Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective vigilantly but unsuccessfully to produce a single therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past few shares. The 1st CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire job interview which I came away with a bad opinion of the business.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, although the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the expertise and associated intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 zillion) as well as the first new drug application approval ($five million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with multiple therapies and numerous indications, it has this individual therapy in addition to a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

The opening banner of its on its website (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple presentations in addition to multiple publications.

Might it all be smoke and mirrors? That is a question I’ve been asking myself with the really start of the interest of mine in this particular organization. Judging with the multiples of a huge number of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *